SOPHiA GENETICS (NASDAQ:SOPH) Shares Down 5.5% – Time to Sell?

SOPHiA GENETICS SA (NASDAQ:SOPH)’s stock price dropped 5.5% during mid-day trading on Tuesday. The stock traded as low as $7.80 and last traded at $7.75. 414,599 shares changed hands during mid-day trading, an increase of 36% from the average session volume of 304,445 shares. The stock had previously closed at $8.20.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on SOPH. HC Wainwright increased their price target on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. BTIG Research increased their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Finally, Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $10.00.

SOPHiA GENETICS Stock Performance

The business has a 50-day moving average of $7.78 and a two-hundred day moving average of $6.10. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55. The company has a market cap of $631.69 million, a P/E ratio of -6.55 and a beta of 0.95.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The firm had revenue of $23.31 million for the quarter, compared to analysts’ expectations of $21.72 million. On average, sell-side analysts predict that SOPHiA GENETICS SA will post -0.77 EPS for the current fiscal year.

Insider Activity

In other SOPHiA GENETICS news, Chairman Jurgi Camblong sold 24,381 shares of the stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $6.29, for a total value of $153,356.49. Following the completion of the sale, the chairman directly owned 3,512,822 shares in the company, valued at approximately $22,095,650.38. This trade represents a 0.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Zhenyu Xu sold 17,000 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $7.29, for a total value of $123,930.00. Following the completion of the sale, the insider directly owned 590,887 shares of the company’s stock, valued at approximately $4,307,566.23. This represents a 2.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 217,745 shares of company stock worth $1,560,269 over the last ninety days. 4.88% of the stock is currently owned by corporate insiders.

Institutional Trading of SOPHiA GENETICS

Several large investors have recently bought and sold shares of SOPH. Maven Securities LTD acquired a new position in SOPHiA GENETICS during the 2nd quarter valued at approximately $866,000. AXQ Capital LP acquired a new stake in shares of SOPHiA GENETICS during the second quarter worth $119,000. AWM Investment Company Inc. purchased a new stake in shares of SOPHiA GENETICS during the second quarter valued at $9,809,000. Hennion & Walsh Asset Management Inc. acquired a new position in shares of SOPHiA GENETICS in the 2nd quarter valued at $567,000. Finally, Royal Bank of Canada increased its position in shares of SOPHiA GENETICS by 3,130.2% in the 1st quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock valued at $96,000 after acquiring an additional 18,781 shares during the period. Hedge funds and other institutional investors own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.